The role of vitamin D in human fracture healing: A systematic review of the literature

Bone

Volumn 64, Issue , 2014, Pages 288-297

  Gorter, Erwin A ^a   Hamdy, Neveen A T ^a   Appelman Dijkstra, Natasha M ^a   Schipper, Inger B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone; Calcidiol; Fracture; Fracture healing; Vitamin D; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CYTOKINE; GROWTH FACTOR; SECALCIFEROL; TACALCITOL; VITAMIN D;

BONE DENSITY; CALLUS; CASE CONTROL STUDY; CASE STUDY; CELL FUNCTION; FRACTURE; FRACTURE HEALING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MINERALIZATION; OSTEOBLAST; OSTEOCLAST; REVIEW; SYSTEMATIC REVIEW; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; PHYSIOLOGY;

FRACTURE HEALING; HUMANS; VITAMIN D;

EID: 84900014873     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.026     Document Type: Review

References (161)

1. Schindeler A., McDonald M.M., Bokko P., Little D.G. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol 2008, 19.
2. Marsell R., Einhorn T.A. The biology of fracture healing. Injury 2011, 42:551-555.
3. Tsiridis E., Upadhyay N., Giannoudis P. Molecular aspects of fracture healing: which are the important molecules?. Injury 2007, 38(Suppl. 1).
4. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 2003, 88:873-884.
5. Pape H.C., Marcucio R., Humphrey C., Colnot C., Knobe M., Harvey E.J. Trauma-induced inflammation and fracture healing. J Orthop Trauma 2010, 24.
6. Giannoudis P.V., Einhorn T.A., Marsh D. Fracture healing: the diamond concept. Injury 2007, 38(Suppl. 4):S3-S6.
7. Haussler M.R., Whitfield G.K., Kaneko I., Haussler C.A., Hsieh D., Hsieh J.C., et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int 2013, 92:77-98.
8. Dickie L.J., Church L.D., Coulthard L.R., Mathews R.J., Emery P., McDermott M.F. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford) 2010, 49:1466-1471.
9. Chen F.P., Lee N., Wang K.C., Soong Y.K., Huang K.E. Effect of estrogen and 1alpha,25(OH)2- vitamin D3 on the activity and growth of human primary osteoblast-like cells in vitro. Fertil Steril 2002, 77:1038-1043.
10. Villaggio B., Soldano S., Cutolo M. 1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clin Exp Rheumatol 2012, 30:934-938.
11. Cohen M.L., Douvdevani A., Chaimovitz C., Shany S. Regulation of TNF-alpha by 1alpha,25-dihydroxyvitamin D3 in human macrophages from CAPD patients. Kidney Int 2001, 59:69-75.
12. Di R.M., Malaguarnera G., De G.C., Palumbo M., Nunnari G., Malaguarnera L. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cell Immunol 2012, 280:36-43.
13. Hustmyer F.G., Girasole G., Manolagas S.C. Signal-dependent pleiotropic regulation of lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3: potent modulation of the hormonal effects by phorbol esters. Immunology 1992, 77:520-526.
14. Katakami N., Nakao Y., Fujita T. Suppressive effect of 1,25(OH)2D3, and glucocorticoids on production of tumor necrosis factor-alpha by human peripheral blood adherent cells. Kobe J Med Sci 1991, 37:179-188.
15. Kuo Y.T., Kuo C.H., Lam K.P., Chu Y.T., Wang W.L., Huang C.H., et al. Effects of vitamin D3 on expression of tumor necrosis factor-alpha and chemokines by monocytes. J Food Sci 2010, 75:H200-H204.
16. Muller K., Diamant M., Bendtzen K. Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett 1991, 28:115-120.
17. Panichi V., De P.S., Andreini B., Bianchi A.M., Migliori M., Taccola D., et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998, 54:1463-1469.
18. Saggese G., Federico G., Cinquanta L. In vitro effects of growth hormone and other hormones on chondrocytes and osteoblast-like cells. Acta Paediatr Suppl 1993, 82(Suppl. 391):54-59.
19. Tsoukas C.D., Watry D., Escobar S.S., Provvedini D.M., Dinarello C.A., Hustmyer F.G., et al. Inhibition of interleukin-1 production by 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1989, 69:127-133.
20. Tsukamoto Y., Nagaba Y., Izumida I., Morishita T., Saitoh M. Comparison of effects of calcitriol and calcium carbonate on secretion of interleukin-1 beta and tumour necrosis factor-alpha by uraemic peripheral blood mononuclear cells. Nephrol Dial Transplant 1996, 11(Suppl. 3):15-21.
21. Yaron I., Meyer F.A., Weisman Y., Yaron M. Effect of 1,25-dihydroxyvitamin D3 on interleukin 1 beta actions and cell growth in human synovial fibroblast cultures. J Rheumatol 1993, 20:1527-1532.
22. Zarrabeitia M.T., Riancho J.A., Amado J.A., Olmos J.M., Gonzalez-Macias J. Effect of calcitriol on the secretion of prostaglandin E2, interleukin 1, and tumor necrosis factor alpha by human monocytes. Bone 1992, 13:185-189.
23. Lee B.N., Kim T.H., Jun J.B., Yoo D.H., Woo J.H., Choi S.J., et al. Upregulation of interleukin-1beta production by 1,25-dihydroxyvitamin D(3) in activated human macrophages. Mol Biol Rep 2011, 38:2193-2201.
24. Bermudez L.E., Young L.S., Gupta S. 1,25 Dihydroxyvitamin D3-dependent inhibition of growth or killing of Mycobacterium avium complex in human macrophages is mediated by TNF and GM-CSF. Cell Immunol 1990, 127:432-441.
25. Bhalla A.K., Amento E.P., Krane S.M. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol 1986, 98:311-322.
26. Bhalla A.K., Paavonen T., Williams M.M., Delves P.J., Lydyard P.M. Regulation of interleukin-1 and tumour necrosis factor gene expression in myelomonocytic cell lines by 1,25-dihydroxyvitamin D3. Immunology 1991, 72:61-64.
27. Haran N., Gurwicz S., Gallati H., Shalita B., Bar-Khayim Y. Effect of 1 alpha-hydroxyvitamin D3 treatment on production of tumor necrosis factor-alpha by peripheral blood mononuclear cells and on serum concentrations of soluble tumor necrosis factor receptors in hemodialysis patients. Nephron 1994, 66:262-266.
28. Prehn J.L., Fagan D.L., Jordan S.C., Adams J.S. Potentiation of lipopolysaccharide-induced tumor necrosis factor-alpha expression by 1,25-dihydroxyvitamin D3. Blood 1992, 80:2811-2816.
29. Spear G.T., Paulnock D.M., Helgeson D.O., Borden E.C. Requirement of differentiative signals of both interferon-gamma and 1,25-dihydroxyvitamin D3 for induction and secretion of interleukin-1 by HL-60 cells. Cancer Res 1988, 48:1740-1744.
30. Srviastava M.D., DeLuca H., Ambrus J.L. Inhibition of IL-6 and IL-8 production in human fibroblast cell lines by 1,25 (OH)2 vitamin D3 and two of its analogs with lower calcemic activity. Res Commun Chem Pathol Pharmacol 1994, 83:145-150.
31. Gurlek A., Pittelkow M.R., Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev 2002, 23.
32. Torricelli P., Fini M., Giavaresi G., Giardino R. Human osteoblast cultures from osteoporotic and healthy bone: biochemical markers and cytokine expression in basal conditions and in response to 1,25(OH)2D3. Artif Cells Blood Substit Immobil Biotechnol 2002, 30:219-227.
33. Hogasen A.K., Nordsletten L., Aasen A.O., Falch J.A. 17 beta-Oestradiol and 1 alpha,25-dihydroxycholecalciferol modulate constitutive and bone matrix-induced interleukin-1 beta (IL-1 beta) production by peripheral blood mononuclear cells isolated from postmenopausal women. Scand J Clin Lab Invest 1998, 58:97-102.
34. Littlewood A.J., Russell J., Harvey G.R., Hughes D.E., Russell R.G., Gowen M. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 1991, 129:1513-1520.
35. Barker T., Martins T.B., Hill H.R., Kjeldsberg C.R., Dixon B.M., Schneider E.D., et al. Circulating pro-inflammatory cytokines are elevated and peak power output correlates with 25-hydroxyvitamin D in vitamin D insufficient adults. Eur J Appl Physiol 2013, 113:1523-1534.
36. Borazan A., Ustun H., Cefle A., Sekitmez N., Yilmaz A. Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels. J Int Med Res 2003, 31:489-496.
37. Muller K., Gram J., Bollerslev J., Diamant M., Barington T., Hansen M.B., et al. Down-regulation of monocyte functions by treatment of healthy adults with 1 alpha,25 dihydroxyvitamin D3. Int J Immunopharmacol 1991, 13:525-530.
38. Turk S., Akbulut M., Yildiz A., Gurbilek M., Gonen S., Tombul Z., et al. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 2002, 90:188-194.
39. Riancho J.A., Zarrabeitia M.T., de Francisco A.L., Amado J.A., Napal J., Arias M., et al. Vitamin D therapy modulates cytokine secretion in patients with renal failure. Nephron 1993, 65:364-368.
40. Alvarez J.A., Zughaier S.M., Law J., Hao L., Wasse H., Ziegler T.R., et al. Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr 2013, 67:264-269.
41. Beilfuss J., Berg V., Sneve M., Jorde R., Kamycheva E. Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine 2012, 60:870-874.
42. Grossmann R.E., Zughaier S.M., Liu S., Lyles R.H., Tangpricha V. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr 2012, 66:1072-1074.
43. Shab-Bidar S., Neyestani T.R., Djazayery A., Eshraghian M.R., Houshiarrad A., Kalayi A., et al. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev 2012, 28:424-430.
44. Stubbs J.R., Idiculla A., Slusser J., Menard R., Quarles L.D. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010, 21:353-361.
45. Bucharles S., Barberato S.H., Stinghen A.E., Gruber B., Piekala L., Dambiski A.C., et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr 2012, 22:284-291.
46. Jamali Z., Arababadi M.K., Asadikaram G. Serum levels of IL-6, IL-10, IL-12, IL-17 and IFN-gamma and their association with markers of bone metabolism in vitamin D-deficient female students. Inflammation 2013, 36:164-168.
47. Gannage-Yared M.H., Azoury M., Mansour I., Baddoura R., Halaby G., Naaman R. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest 2003, 26:748-753.
48. Assimon M.M., Salenger P.V., El-Fawal H.A., Mason D.L. Nutritional vitamin D supplementation in haemodialysis: a potential vascular benefit?. Nephrology (Carlton) 2012, 17:237-242.
49. Inanir A., Ozoran K., Tutkak H., Mermerci B. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis. J Int Med Res 2004, 32.
50. Peterson C.A., Heffernan M.E. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm 2008, 5.
51. Eleftheriadis T., Antoniadi G., Liakopoulos V., Stefanidis I., Galaktidou G. Inverse association of serum 25-hydroxyvitamin D with markers of inflammation and suppression of osteoclastic activity in hemodialysis patients. Iran J Kidney Dis 2012, 6.
52. Khoo A.L., Chai L.Y., Koenen H.J., Sweep F.C., Joosten I., Netea M.G., et al. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol 2011, 164:72-79.
53. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83:754-759.
54. Miller R.R., Hicks G.E., Shardell M.D., Cappola A.R., Hawkes W.G., Yu-Yahiro J.A., et al. Association of serum vitamin D levels with inflammatory response following hip fracture: the Baltimore Hip Studies. J Gerontol A Biol Sci Med Sci 2007, 62:1402-1406.
55. van Leeuwen J.P., van Driel M., van den Bemd G.J., Pols H.A. Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr 2001, 11.
56. Wu Y., Haugen J.D., Zinsmeister A.R., Kumar R. 1 alpha,25-Dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells. Biochem Biophys Res Commun 1997, 239:734-739.
57. Nagel D., Kumar R. 1 alpha,25-dihydroxyvitamin D3 increases TGF beta 1 binding to human osteoblasts. Biochem Biophys Res Commun 2002, 290:1558-1563.
58. Sugimoto I., Hirakawa K., Ishino T., Takeno S., Yajin K. Vitamin D3, vitamin K2, and warfarin regulate bone metabolism in human paranasal sinus bones. Rhinology 2007, 45:208-213.
59. Mahon B.D., Gordon S.A., Cruz J., Cosman F., Cantorna M.T. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003, 134:128-132.
60. Isik S., Ozuguz U., Tutuncu Y.A., Erden G., Berker D., Acar K., et al. Serum transforming growth factor-beta levels in patients with vitamin D deficiency. Eur J Intern Med 2012, 23:93-97.
61. Virdi A.S., Cook L.J., Oreffo R.O., Triffitt J.T. Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Cell Mol Biol (Noisy-le-grand) 1998, 44:1237-1246.
62. Faucheux C., Bareille R., Amedee J., Triffitt J.T. Effect of 1,25(OH)2D3 on bone morphogenetic protein-3 mRNA expression. J Cell Biochem 1999, 73:11-19.
63. Wang D.S., Miura M., Demura H., Sato K. Anabolic effects of 1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology 1997, 138:2953-2962.
64. Neve A., Cantatore F.P., Corrado A., Gaudio A., Ruggieri S., Ribatti D. In vitro and in vivo angiogenic activity of osteoarthritic and osteoporotic osteoblasts is modulated by VEGF and vitamin D3 treatment. Regul Pept 2013, 184:81-84.
65. Wang D.S., Yamazaki K., Nohtomi K., Shizume K., Ohsumi K., Shibuya M., et al. Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells. J Bone Miner Res 1996, 11:472-479.
66. Corrado A., Neve A., Cantatore F.P. Expression of vascular endothelial growth factor in normal, osteoarthritic and osteoporotic osteoblasts. Clin Exp Med 2013, 13:81-84.
67. Schlaeppi J.M., Gutzwiller S., Finkenzeller G., Fournier B. 1,25-Dihydroxyvitamin D3 induces the expression of vascular endothelial growth factor in osteoblastic cells. Endocr Res 1997, 23:213-229.
68. Gruber H.E., Hoelscher G., Ingram J.A., Chow Y., Loeffler B., Hanley E.N. 1,25(OH)2-vitamin D3 inhibits proliferation and decreases production of monocyte chemoattractant protein-1, thrombopoietin, VEGF, and angiogenin by human annulus cells in vitro. Spine (Phila Pa 1976) 2008, 33:755-765.
69. Ito M., Azuma Y., Ohta T., Komoriya K. Effects of ultrasound and 1,25-dihydroxyvitamin D3 on growth factor secretion in co-cultures of osteoblasts and endothelial cells. Ultrasound Med Biol 2000, 26.
70. Pedigo N., Zhang H., Koszewski N.J., Kaetzel D.M. A 5'-distal element mediates vitamin D-inducibility of PDGF-A gene transcription. Growth Factors 2003, 21:151-160.
71. Scharla S.H., Strong D.D., Rosen C., Mohan S., Holick M., Baylink D.J., et al. 1,25-Dihydroxyvitamin D3 increases secretion of insulin-like growth factor binding protein-4 (IGFBP-4) by human osteoblast-like cells in vitro and elevates IGFBP-4 serum levels in vivo. J Clin Endocrinol Metab 1993, 77:1190-1197.
72. Chenu C., Valentin-Opran A., Chavassieux P., Saez S., Meunier P.J., Delmas P.D. Insulin like growth factor I hormonal regulation by growth hormone and by 1,25(OH)2D3 and activity on human osteoblast-like cells in short-term cultures. Bone 1990, 11:81-86.
73. Fernandez-Cancio M., Audi L., Carrascosa A., Toran N., Andaluz P., Esteban C., et al. Vitamin D and growth hormone regulate growth hormone/insulin-like growth factor (GH-IGF) axis gene expression in human fetal epiphyseal chondrocytes. Growth Horm IGF Res 2009, 19:232-237.
74. Geng S., Zhou S., Bi Z., Glowacki J. Vitamin D metabolism in human bone marrow stromal (mesenchymal stem) cells. Metabolism 2013, 62(6):768-777. (Jun).
75. Kveiborg M., Flyvbjerg A., Eriksen E.F., Kassem M. 1,25-Dihydroxyvitamin D3 stimulates the production of insulin-like growth factor-binding proteins-2, -3 and -4 in human bone marrow stromal cells. Eur J Endocrinol 2001, 144:549-557.
76. Ameri P., Giusti A., Boschetti M., Murialdo G., Minuto F., Ferone D. Interactions between vitamin D and IGF-I: from physiology to clinical practice. Clin Endocrinol (Oxf) 2013, 79:457-463.
77. Soliman A.T., Al K.F., Alhemaidi N., Al A.M., Al Z.M., Yakoot K. Linear growth in relation to the circulating concentrations of insulin-like growth factor I, parathyroid hormone, and 25-hydroxy vitamin D in children with nutritional rickets before and after treatment: endocrine adaptation to vitamin D deficiency. Metabolism 2008, 57:95-102.
78. Zofkova I., Kancheva R.L., Bendlova B. Effect of 1,25(OH)2 vitamin D3 on circulating insulin-like growth factor-I and beta 2 microglobulin in patients with osteoporosis. Calcif Tissue Int 1997, 60:236-239.
79. Bogazzi F., Rossi G., Lombardi M., Tomisti L., Sardella C., Manetti L., et al. Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects. J Endocrinol Invest 2011, 34:e200-e203.
80. Kamycheva E., Berg V., Jorde R. Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects. Endocrine 2013, 43:412-418.
81. Anderson P.H., Atkins G.J. The skeleton as an intracrine organ for vitamin D metabolism. Mol Aspects Med 2008, 29.
82. van den Bemd G.J., Pols H.A., Birkenhager J.C., Kleinekoort W.M., van Leeuwen J.P. Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption. J Steroid Biochem Mol Biol 1995, 55:337-346.
83. Geng S., Zhou S., Glowacki J. Effects of 25-hydroxyvitamin D(3) on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1alpha-hydroxylase. J Bone Miner Res 2011, 26:1145-1153.
84. Adelina C.M., Helena F.M. Long-term effects of parathyroid hormone, 1,25-dihydroxyvitamin d(3), and dexamethasone on the cell growth and functional activity of human osteogenic alveolar bone cell cultures. Pharmacol Res 2000, 42:345-353.
85. Zhou S., Glowacki J., Kim S.W., Hahne J., Geng S., Mueller S.M., et al. Clinical characteristics influence in vitro action of 1,25-dihydroxyvitamin D(3) in human marrow stromal cells. J Bone Miner Res 2012, 27:1992-2000.
86. Tasaki Y., Takamori R., Koshihara Y. Prostaglandin D2 metabolite stimulates collagen synthesis by human osteoblasts during calcification. Prostaglandins 1991, 41:303-313.
87. Fromigue O., Marie P.J., Lomri A. Differential effects of transforming growth factor beta2, dexamethasone and 1,25-dihydroxyvitamin D on human bone marrow stromal cells. Cytokine 1997, 9:613-623.
88. Ingram R.T., Bonde S.K., Riggs B.L., Fitzpatrick L.A. Effects of transforming growth factor beta (TGF beta) and 1,25 dihydroxyvitamin D3 on the function, cytochemistry and morphology of normal human osteoblast-like cells. Differentiation 1994, 55:153-163.
89. Morike M., Schulz M., Nerlich A., Koschnik M., Teller W.M., Vetter U., et al. Expression of osteoblastic markers in cultured human bone and fracture callus cells. J Mol Med (Berl) 1995, 73:571-575.
90. Siu-Caldera M.L., Zou L., Ehrlich M.G., Schwartz E.R., Ishizuka S., Reddy G.S. Human osteoblasts in culture metabolize both 1 alpha, 25-dihydroxyvitamin D3 and its precursor 25-hydroxyvitamin D3 into their respective lactones. Endocrinology 1995, 136:4195-4203.
91. Anderson P.H., Atkins G.J., Turner A.G., Kogawa M., Findlay D.M., Morris H.A. Vitamin D metabolism within bone cells: effects on bone structure and strength. Mol Cell Endocrinol 2011, 347.
92. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007, 40.
93. van Driel M., Koedam M., Buurman C.J., Hewison M., Chiba H., Uitterlinden A.G., et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 2006, 20:2417-2419.
94. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005, 289.
95. Orimo H. The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch 2010, 77.
96. Bosetti M., Boccafoschi F., Leigheb M., Cannas M.F. Effect of different growth factors on human osteoblasts activities: a possible application in bone regeneration for tissue engineering. Biomol Eng 2007, 24:613-618.
97. Woeckel V.J., Alves R.D., Swagemakers S.M., Eijken M., Chiba H., van der Eerden B.C., et al. 1Alpha,25-(OH)2D3 acts in the early phase of osteoblast differentiation to enhance mineralization via accelerated production of mature matrix vesicles. J Cell Physiol 2010, 225:593-600.
98. Woeckel V.J., Bruedigam C., Koedam M., Chiba H., van der Eerden B.C., van Leeuwen J.P. 1alpha,25-dihydroxyvitamin D3 and rosiglitazone synergistically enhance osteoblast-mediated mineralization. Gene 2013, 512:438-443.
99. van Driel M., Koedam M., Buurman C.J., Roelse M., Weyts F., Chiba H., et al. Evidence that both 1 alpha,25-dihydroxyvitamin D-3 and 24-hydroxylated D-3 enhance human osteoblast differentiation and mineralization. J Cell Biochem 2006, 99:922-935.
100. Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol 2010, 25.
101. Alon U.S. Clinical practice. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr 2011, 170.
102. Liu S., Quarles L.D. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007, 18:1637-1647.
103. Turner C., Dalton N., Inaoui R., Fogelman I., Fraser W.D., Hampson G. Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency. J Clin Endocrinol Metab 2013, 98:550-556.
104. Uzum A.K., Salman S., Telci A., Boztepe H., Tanakol R., Alagol F., et al. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol 2010, 163:825-831.
105. Kogawa M., Anderson P.H., Findlay D.M., Morris H.A., Atkins G.J. The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. J Steroid Biochem Mol Biol 2010, 121.
106. Mee A.P., Hoyland J.A., Braidman I.P., Freemont A.J., Davies M., Mawer E.B. Demonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in bone sections. Bone 1996, 18:295-299.
107. Qi D.Y., Perkins S.L., Kling S.J., Russell R.G. Divergent regulation of 1,25-dihydroxyvitamin D3 on human bone marrow osteoclastogenesis and myelopoiesis. J Cell Biochem 1999, 72:387-395.
108. Thavarajah M., Evans D.B., Kanis J.A. 1,25(OH)2D3 induces differentiation of osteoclast-like cells from human bone marrow cultures. Biochem Biophys Res Commun 1991, 176:1189-1195.
109. Flanagan A.M., Stow M.D., Kendall N., Brace W. The role of 1,25-dihydroxycholecalciferol and prostaglandin E2 in the regulation of human osteoclastic bone resorption in vitro. Int J Exp Pathol 1995, 76:37-42.
110. Atkins G.J., Kostakis P., Pan B., Farrugia A., Gronthos S., Evdokiou A., et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003, 18:1088-1098.
111. Kudo O., Sabokbar A., Pocock A., Itonaga I., Athanasou N.A. Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts. Calcif Tissue Int 2002, 71:539-546.
112. Kim T.H., Lee B., Kwon E., Choi C.H., Sung I.H., Kim Y., et al. 1,25-Dihydroxyvitamin D3 inhibits directly human osteoclastogenesis by down-regulation of the c-Fms and RANK expression. Joint Bone Spine 2013, 80:307-314.
113. Braun J.J., Birkenhager-Frenkel D.H., Rietveld A.H., Juttmann J.R., Visser T.J., Birkenhager J.C. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study. Clin Endocrinol (Oxf) 1983, 19:265-273.
114. Kogawa M., Findlay D.M., Anderson P.H., Ormsby R., Vincent C., Morris H.A., et al. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology 2010, 151.
115. Alkalay D., Shany S., Dekel S. Serum and bone vitamin D metabolites in elective patients and patients after fracture. J Bone Joint Surg 1989, 71.
116. Briggs A.D., Kuan V., Greiller C.L., Maclaughlin B.D., Ramachandran M., Harris T., et al. Longitudinal study of vitamin D metabolites after long bone fracture. J Bone Miner Res 2013, 28:1301-1307.
117. Meller Y., Shainkin-Kestenbaum R., Shany S., Zuilli I., Yankowitz N., Giat J., et al. Parathyroid hormone, calcitonin, and vitamin D metabolites during normal fracture healing in humans. A preliminary report. Clin. Orthop. Relat. Res. 1984, (183):238-245. [Mar].
118. Meller Y., Kestenbaum R.S., Shany S. Parathormone, calcitonin, and vitamin D metabolites during normal fracture healing in geriatric patients. Clin Orthop Relat Res 1985, 199. [NO.].
119. Wölfl C., Englert S., Moghaddam A.A., Zimmermann G., Schmidt-Gayk G., Honer B., et al. Time course of 25(OH)D3 vitamin D3 as well as PTH (parathyroid hormone) during fracture healing of patients with normal and low bone mineral density (BMD). BMC Musculoskelet Disord 2013, 14:6.
120. Sakuma M., Endo N., Minato I., Toyama H., Endo E. Changes in serum 25-hydroxycholecalciferol and intact parathyroid hormone status after hip fracture. Acta Med Biol 2006, 54. [September].
121. Yu-Yahiro J.A., Michael R.H., Dubin N.H., Fox K.M., Sachs M., Hawkes W.G., et al. Serum and urine markers of bone metabolism during the year after hip fracture. J Am Geriatr Soc 2001, 49:877-883.
122. Brinker M.R., O'Connor D.P., Monla Y.T., Earthman T.P. Metabolic and endocrine abnormalities in patients with nonunions. J Orthop Trauma 2007, 21.
123. Tauber C., Noff D., Noff M., Malkin C. Blood levels of active metabolites of vitamin D3 in fracture repair in humans. A preliminary report. Arch Orthop Trauma Surg 1990, 109.
124. Boszczyk A.M., Zakrzewski P., Pomianowski S. Vitamin D concentration in patients with normal and impaired bone union. Pol Orthop Traumatol 2013, 78:1-3.
125. Haining S.A., Atkins R.M., Guilland-Cumming D.F., Sharrard W.J., Russell R.G., Kanis J.A. Vitamin D metabolites in patients with established non-union of fracture. Bone Miner 1986, 1.
126. Doetsch A.M., Faber J., Lynnerup N., Watjen I., Bliddal H., Danneskiold-Samsoe B. The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized placebo-controlled study. Calcif Tissue Int 2004, 75.
127. Hoikka V., Alhava E.M., Aro A., Karjalainen P., Rehnberg V. Treatment of osteoporosis with 1-alpha-hydroxycholecalciferol and calcium. Acta Med Scand 1980, 207:221-224.
128. Kolb J.P., Schilling A.F., Bischoff J., Novo de O.A., Spiro A., Hoffmann M., et al. Calcium homeostasis influences radiological fracture healing in postmenopausal women. Arch Orthop Trauma Surg 2013, 133:187-192.
129. Jingushi S., Iwaki A., Higuchi O., Azuma Y., Ohta T., Shida J.I., et al. Serum 1alpha,25-dihydroxyvitamin D3 accumulates into the fracture callus during rat femoral fracture healing. Endocrinology 1998, 139.
130. Lidor C., Dekel S., Edelstein S. The metabolism of vitamin D3 during fracture healing in chicks. Endocrinology 1987, 120.
131. Lidor C., Dekel S., Hallel T., Edelstein S. Levels of active metabolites of vitamin D3 in the callus of fracture repair in chicks. J Bone Joint Surg 1987, 69.
132. Kato A., Bishop J.E., Norman A.W. Evidence for a 1 alpha,25-dihydroxyvitamin D3 receptor/binding protein in a membrane fraction isolated from a chick tibial fracture-healing callus. Biochem Biophys Res Commun 1998, 244.
133. Kato A., Seo E.G., Einhorn T.A., Bishop J.E., Norman A.W. Studies on 24R,25-dihydroxyvitamin D3: evidence for a nonnuclear membrane receptor in the chick tibial fracture-healing callus. Bone 1998, 23.
134. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012, 97:1153-1158.
135. Mithal A., Wahl D.A., Bonjour J.P., Burckhardt P., Dawson-Hughes B., Eisman J.A., et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009, 20:1807-1820.
136. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.
137. Brouwer-Brolsma E.M., Bischoff-Ferrari H.A., Bouillon R., Feskens E.J., Gallagher C.J., Hypponen E., et al. Vitamin D: do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe. Osteoporos Int 2013, 24:1567-1577.
138. Bischoff-Ferrari H.A., Willett W.C., Orav E.J., Lips P., Meunier P.J., Lyons R.A., et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012, 367:40-49.
139. Brumbaugh P.F., Speer D.P., Pitt M.J. 1 alpha, 25-Dihydroxyvitamin D3 a metabolite of vitamin D that promotes bone repair. Am J Pathol 1982, 106.
140. Dekel S., Salama R., Edelstein S. The effect of vitamin D and its metabolites on fracture repair in chicks. Clin Sci (Lond) 1983, 65.
141. Einhorn T.A., Bonnarens F., Burstein A.H. The contributions of dietary protein and mineral to the healing of experimental fractures. A biomechanical study. J Bone Joint Surg Am 1986, 68.
142. Lindholm T.S., Hackman R., Lindholm R.V., Kinnunen P. Fracture callus and mast cells in rats with calcium and vitamin D deficiency. Acta Orthop Scand 1972, 43:221-233.
143. Melhus G., Solberg L.B., Dimmen S., Madsen J.E., Nordsletten L., Reinholt F.P. Experimental osteoporosis induced by ovariectomy and vitamin D deficiency does not markedly affect fracture healing in rats. Acta Orthop 2007, 78:393-403.
144. Andreen O., Larsson S.E. Effects of 1,25-dihydroxycholecalciferol on fracture healing. Calcium, phosphate, and zinc in callus and serum. Arch Orthop Trauma Surg 1984, 103.
145. Steier A., Gedalia I., Schwarz A., Rodan A. Effect of vitamin D2 and fluoride on experimental bone fracture healing in rats. J Dent Res 1967, 46.
146. Fu L., Tang T., Miao Y., Hao Y., Dai K. Effect of 1,25-dihydroxy vitamin D3 on fracture healing and bone remodeling in ovariectomized rat femora. Bone 2009, 44.
147. Lindgren J.U., Narechania R.G., McBeath A.A. Effects of 1.25 dihydroxyvitamin D3 and calcitonin on fracture healing in adult rats. Clin Orthop Relat Res 1981, 160. [No.].
148. Akkaya S., Nazali M., Kilic A., Bir F. Cefazolin-sodium has no adverse effect on fracture healing in an experimental rabbit model. Eklem Hastalik Cerrahisi 2012, 23:44-48.
149. Omeroglu S., Erdogan D., Omeroglu H. Effects of single high-dose vitamin D3 on fracture healing. An ultrastructural study in healthy guinea pigs. Arch Orthop Trauma Surg 1997, 116.
150. Norman A.W., Okamura W.H., Bishop J.E., Henry H.L. Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R,25(OH)2-vitamin D3. Mol Cell Endocrinol 2002, 197.
151. Saito M., Shiraishi A., Ito M., Sakai S., Hayakawa N., Mihara M., et al. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 2010, 46.
152. Lidor C., Dekel S., Meyer M.S., Blaugrund E., Hallel T., Edelstein S. Biochemical and biomechanical properties of avian callus after local administration of dihydroxylated vitamin D metabolites. J Bone Joint Surg 1990, 72.
153. Seo E.G., Einhorn T.A., Norman A.W. 24R,25-dihydroxyvitamin D3: an essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks. Endocrinology 1997, 138.
154. Aslan B., Kalaci A., Bozlar M., Atik E., Yanat A.N., Tasci A. Effects of vitamin D3 and calcium on fracture healing in rats. Turkiye Klinikleri J Med Sci 2006, 26.
155. Delgado-Martinez A.D., Martinez M.E., Carrascal M.T., Rodriguez-Avial M., Munuera L. Effect of 25-OH-vitamin D on fracture healing in elderly rats. J Orthop Res 1998, 16.
156. Omeroglu H., Ates Y., Akkus O., Korkusuz F., Bicimoglu A., Akkas N. Biomechanical analysis of the effects of single high-dose vitamin D3 on fracture healing in a healthy rabbit model. Arch Orthop Trauma Surg 1997, 116.
157. Lindholm T.S., Sevastikoglou J.A. The effect of 1alpha-hydroxycholecalciferol on the healing of experimental fractures in adult rats. Acta Orthop Scand 1978, 49.
158. Dekel S., Ornoy A., Sekeles E. Contrasting effects on bone formation and on fracture healing of cholecalciferol and of 1 alpha-hydroxycholecalciferol. Calcif Tissue Int 1979, 28.
159. Andreen O., Larsson S.E. Effects of parathyroidectomy and vitamin D on fracture healing. Fracture biomechanics in rats after parathyroidectomy and treatment with 1,25-dihydroxycholecalciferol. Acta Orthop Scand 1983, 54.
160. Cao Y., Mori S., Mashiba T., Kaji Y., Manabe T., Iwata K., et al. 1Alpha,25-dihydroxy-2beta(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus remodeling but did not interfere with fracture healing in rat femora. Bone 2007, 40.
161. Lindgren J.U., DeLuca H.F., Mazess R.B. Effects of 1,25(OH)2D3 on bone tissue in the rabbit: studies on fracture healing, disuse osteoporosis, and prednisone osteoporosis. Calcif Tissue Int 1984, 36.